Dual-target fusion proteins comprising FGF21 and GLP-1, connected through a Fc portion of an immunoglobulin
US12145974B2 · kind B2 · utility
0Cited by
26References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 14, 2018 |
| Grant date | Nov 19, 2024 |
| Priority date | — |
| Expiry date | Dec 18, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is a fusion protein containing GLP-1 and FGF21 linked through an immunoglobulin Fc portion. Each of the GLP-1 and FGF21 can be substituted with its analogues or variants and, the Fc portion, which can be derived from IgG4, can include substitutions that further enhance the fusion protein's stability and activity. These fragments can be linked together through peptide linkers. The fusion protein can be used clinically to reduce glucose and lipid levels and body weight.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.